Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Neural Computation|August 25, 2016
On the Analytical Solution of Firing Time for SpikePropSimon de Montigny, Benoît R MâsseJournal of Acquired Immune Deficiency Syndromes (1999)|March 19, 2016
PrEP Adherence Patterns Strongly Affect Individual HIV Risk and Observed Efficacy in Randomized Clinical TrialsDobromir T Dimitrov, Benoît R Mâsse, Deborah DonnellJournal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2012
Beating the placebo in HIV prevention efficacy trials: the role of the minimal efficacy boundDobromir T Dimitrov, Benoît R Mâsse, Marie-Claude BoilyJournal of the American Statistical Association|May 14, 2013
Partially hidden Markov model for time-varying principal stratification in HIV prevention trialsJames Y Dai, Peter B Gilbert, Benoît R MâsseEmerging Themes in Epidemiology|October 13, 2009
Efficacy dilution in randomized placebo-controlled vaginal microbicide trialsBenoît R Mâsse, Marie-Claude Boily, Dobromir Dimitrov, et al.Journal of AIDS & Clinical Research|December 28, 2013
Impact of Pill Sharing on Drug Resistance Due to a Wide-Scale Oral Prep Intervention in Generalized EpidemicsDobromir Dimitrov, Marie-Claude Boily, Benoît R Mâsse, et al.Infectious Disease Modelling|March 7, 2019
Assessing the utility of the tipping point ratio to monitor HIV treatment programmes in the era of universal access to ARTSimon de Montigny, Marie-Claude Boily, Benoît R Mâsse, et al.Emerging Themes in Epidemiology|December 26, 2006
The role of sexually transmitted infections in male circumcision effectiveness against HIV--insights from clinical trial simulationKamal Desai, Marie-Claude Boily, Geoff P Garnett, et al.Scientific Reports|April 19, 2018
Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling studySimon de Montigny, Blythe J S Adamson, Benoît R Mâsse, et al.Journal of the International AIDS Society|September 5, 2012
Utility of colposcopy in a phase 2 portion of a microbicide clinical trial of BufferGel and 0.5% PRO 2000 GelZvavahera M Chirenje, Benoît R Mâsse, Lisa A Maslankowski, et al.Pageof 1